Feedback
Health

Stem Cell Controversy Sets Back Japanese Science

The finding that a researcher falsified data in a widely heralded stem-cell research paper is a setback for Japan's efforts to promote its advanced research, experts say.

The government-funded Riken Center for Development Biology in Kobe, Japan said Tuesday it had found malpractice by scientist Haruko Obokata in the work on using a simple lab procedure to grow tissue for treating illnesses such as diabetes and Parkinson's disease.

Obokata disputed the allegations, saying in a statement issued by Riken that she plans to appeal the findings issued by a committee set up to investigate discrepancies in the research published in January in the scientific journal Nature.

Nature has refused comment on whether the paper might be retracted but said it is conducting its own evaluation and considering Riken's findings.

Shunsuke Ishii, chairman of the investigating panel at Riken, told reporters Tuesday that Obokata had said she altered images used in the research to make the results "look more beautiful." Data she recorded also was fragmented and incomplete, he said.

Obokata said some of the images were chosen by mistake. The institute said it would take months more to determine whether the stem cell findings are valid regardless of any questions about the data. Obokata asserts the findings are genuine.

The developments at Riken are a setback for government efforts to market Japan's research and development expertise as a 21st century industry needed to revitalize the country's manufacturing.

Arthur Caplan, an expert on bioethics at New York University Langone Medical Center, said the doubts about the research are a "devastating blow" for Japanese science. "The government has invested in cutting edge bioscience to promote Japan's economy, so the revelation of fraud and misconduct at a major institute is both an embarrassment for the government and a huge setback for the Japanese research community," he said.

Scientists hope to harness stem cells to replace defective tissue in a wide variety of diseases. Making stem cells from a patient would eliminate the risk of transplant rejection.

The researchers in Boston and Japan participating in the project used a simple procedure to turn ordinary cells from mice into stem cells by exposing cells from spleens of newborn mice to a more acidic environment than they are used to.